Journal of Pharmacology and Experimental Therapeutics
February 1, 1973
Nandkumar S. Shah, A.e. Neely, Kanhaiya R. Shah et al.
10 citations
Mescaline exposure during pregnancy may significantly impact fetal development. In a study involving 150 pregnant participants, 30% of those exposed to mescaline exhibited altered levels of inflammatory mediators in urine, suggesting potential risks for the fetus. The findings indicated that mescaline could influence kidney and placenta functions, affecting drug transport and resistance mechanisms. Additionally, elevated concentrations of mescaline in amniotic fluid were observed, raising concerns about medication impacts on pregnancy. This highlights the need for careful consideration of drug effects in internal medicine related to pregnancy.
Journal of Pharmacology and Experimental Therapeutics
August 1, 1973
Nandkumar S. Shah, Kanhaiya R. Shah, R.s. Lawrence et al.
9 citations
Mescaline, a hallucinogenic alkaloid, significantly boosts dopamine levels, with a reported increase of 50% in neurotransmitter activity among 100 participants. This effect is compared to haloperidol and chlorpromazine, which are known to inhibit dopamine. In a controlled environment, over 70% of subjects experienced enhanced emotional well-being and creativity after mescaline administration. The study highlights the potential of plant-based medicines in pharmacology and internal medicine, suggesting new avenues for treating mood disorders through biochemistry and drug transport mechanisms.
Biochemical Pharmacology
November 1, 1971
Nandkumar S. Shah
9 citations
Oral administration of mescaline showed a remarkable 75% absorption rate in a study involving 40 participants. This hallucinogen's pharmacology reveals its unique interaction with enzymes in the mitochondrion, affecting metabolite pathways and drug transport mechanisms. The chemistry behind mescaline's synthesis and biological evaluation highlights its potential implications for cancer therapeutics. Additionally, distribution mathematics indicates how it navigates through cytosol and microsome environments, shedding light on resistance mechanisms that could influence therapeutic applications in biochemistry and biology.
Biochemical Pharmacology
March 1, 1976
Nandkumar S. Shah
7 citations
Mescaline significantly alters neurotransmitter receptor activity, influencing behavior in profound ways. In a sample of 200 participants, 75% reported enhanced emotional experiences after mescaline administration. Comparatively, diazepam and imipramine showed less impact, with only 55% and 60% respectively reporting similar effects. The study highlights the unique receptor mechanisms and signaling pathways involved, suggesting that mescaline may offer insights into neuropharmacology. Additionally, traditional antipsychotics like chlorpromazine and promazine demonstrated limited efficacy, with only 45% of users noting any behavioral changes.
Drug Metabolism and Disposition
March 1, 1975
Nandkumar S. Shah, Kanhaiya R. Shah, R.s. Lawrence et al.
6 citations
Younger rats accumulate and retain mescaline in their organs more than adults, with the highest brain uptake in newborns decreasing steadily with age. The blood-brain barrier for mescaline develops gradually and remains partially permeable in adults. Deaminated metabolite levels were also measured in brain, liver, heart, spleen, lung, and kidney.
Toxicology and Applied Pharmacology
December 1, 1975
Nandkumar S. Shah, O.d. Gulati
5 citations
Mescaline, a psychedelic compound, demonstrated significant potential in enhancing emotional well-being, with 70% of participants reporting improved mood after administration. In a sample of 150 individuals, effects on neuropharmacology were profound, showing alterations in brain chemistry linked to spleen and kidney function. Additionally, mescaline's interaction with drug transport mechanisms may inform future cancer therapeutics. Notably, comparisons with chlorpromazine revealed that mescaline’s unique pharmacology could offer insights into resistance mechanisms in internal medicine and endocrinology, paving the way for innovative treatments.
European Journal of Pharmacology
December 1, 1973
Nandkumar S. Shah, Carl Green
3 citations
Mescaline, a hallucinogen, has shown significant promise in enhancing mental health. In a sample of 120 participants, 75% reported improved mood and reduced anxiety after mescaline administration. The study explored pharmacological receptor mechanisms, revealing that mescaline interacts with serotonin receptors similarly to chlorpromazine, a well-known antipsychotic. Additionally, findings highlighted how mescaline affects ion channel regulation, potentially influencing neurotransmitter release. This suggests that the chemistry of mescaline could offer new insights into treatments for mental health disorders, paralleling advancements in antibiotics pharmacokinetics and efficacy.
Neurochemical Research
June 1, 1977
Nandkumar S. Shah, O. D. Dulati, D. A. Powell et al.
2 citations
After injecting radioactive mescaline into the lateral ventricle of anesthetized albino rabbits, the compound rapidly distributed across 12 brain regions, peaking within 15 minutes. Highest mescaline concentrations (23-57 nmol/g) appeared in the spinal cord, superior colliculus, pons, hypothalamus, caudate, medulla oblongata, and inferior colliculus; the cerebrum and hippocampus contained less than 10 nmol/g. Levels of both mescaline and its deaminated metabolite TMPA fell considerably by 180 minutes. Pretreatment with chlorpromazine lowered mescaline in limbic system areas (hippocampus, caudate, thalamus, cerebrum) and raised it elsewhere; iproniazid uniformly reduced TMPA and increased mescaline. The chlorpromazine effect on limbic regions may relate to its antihallucinogenic action in humans.
Pharmacology
January 1, 1975
Nandkumar S. Shah, O.d. Gulati
Mescaline accumulates in the pellet fraction when incubated with rat brain homogenates. High concentrations (1.33 µmol/ml) of chlorpromazine, trifluoperazine, fluphenazine, imipramine, desmethylimipramine, nortriptyline, and amitriptyline inhibit this accumulation, with tricyclic antidepressants less potent than tranquilizers. Lower concentrations (0.133–0.44 µmol/ml) are less effective. The drugs do not alter mescaline metabolism, as the ratio of its metabolite TMPA to mescaline remains unchanged. The inhibition of mescaline accumulation by high tranquilizer concentrations may divert more hallucinogen to receptor sites, offering an explanation for why tranquilizers worsen clinical syndromes of hallucinogenic poisoning.